Stories about Medizinische Behandlung

Isotopia Molecular Imaging

Isotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging

Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark. The introduction of Isoprotrace® into these Nordic markets marks a ...

NeutroFlow

NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response

Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...

Johnson & Johnson MedTech

Personalized Treatment Plans Influence European Public's Willingness to Share Health Data

Leeds, England (ots/PRNewswire) - A global survey reveals Europe's growing confidence in the use of data and technology to transform healthcare and surgery. A global survey from Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, reveals that Europeans are favorable to sharing their health data in exchange for ...

Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...

Helmholtz Munich

Engineering Smart Delivery for Gene Editors

Immunity Pharma

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...

PNO Innovation GmbH

SGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment

GEA Group Aktiengesellschaft

2

GEA presents the kytero® 10, the world's smallest single use disk stack centrifuge

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market

TOOsonix A/S

TOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region

Copenhagen, Denmark (ots/PRNewswire) - A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions - often completed in under 90 seconds. ...

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...

CO.DON GmbH

CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration

Teltow (ots) - The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, ...

Isotopia; Kinectrics

Kinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161) for Advanced Radiotherapeutics

Toronto (ots/PRNewswire) - Kinectrics and Isotopia have announced a groundbreaking agreement under which Kinectrics will provide Isotopia with a reliable supply of Gadolinium-160 (Gd-160). This critical isotope will enable Isotopia's production of Terbium-161 (Tb-161), a medical isotope showing great promise and ...

Norgine

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

BAIBYS

BAIBYS™ Announces a Breakthrough in Fertility Treatment with a Newly CE Marked IVF System

Tel Aviv, Israel (ots/PRNewswire) - The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market BAIBYS™, a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system. This milestone enables the company to ...

Helmholtz Munich

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

BIAL SA

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...

Norgine

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Technische Universität München

Complex pancreatic tumor organoids as foundation for new treatment strategies

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...

European Alliance Against Depression

First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing

Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...

Helmholtz Munich

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...